Transcriptional profiling of anti-CD44-treated persistently adhered AML cells identified them to be enriched in the FAK pathway, and the measurement of FAK phosphorylation confirmed an increase FAK signaling, indicating that the inhibition of this in combination with anti-CD44 could be a promising therapeutic strategy. The gene discussed is CD44; the disease is acute myeloid leukemia.